Collection size

• > 8.500 original (proprietary) compounds (approx. 5mg to > 50 mg, chemically characterized)
• 200 reference compounds for benchmark evaluation

Origin

• chemical synthesis (output of >30 years medicinal chemistry research in the Laufer group)

Key Features

• mainly small series of 20-200 cpds
• 7.500 protein kinase inhibitors with focus on autoimmune and oncology targets, such as
  • p38a, b, g, d; JNK1,2,3; JAK1,2,3 Tyk2; CK1d,e; GSK3b,
  • EGFRs wt and mts, VEGFRs, PI3Ks, Aurora A, MKK4
• 1.000 eicosanoid modulators, targeting COX-1,2,3; 5-,12-,15-LOX, cPLA2, mPGES1
• > 25.000 liquid samples (10 mM DMSO Stock)